These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21069463)

  • 1. Exacerbation of erythropoietic protoporphyria by hyperthyroidism.
    Minder EI; Haldemann AR; Schneider-Yin X
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S465-9. PubMed ID: 21069463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and molecular diagnosis of erythropoietic protoporphyria in an Ashkenazi Jewish family.
    Schneider-Yin X; Mamet R; Minder EI; Schoenfeld N
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S363-7. PubMed ID: 18758989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors of hepatic dysfunction in patients with Graves' hyperthyroidism and the efficacy of 131iodine treatment.
    Wang R; Tan J; Zhang G; Zheng W; Li C
    Medicine (Baltimore); 2017 Feb; 96(5):e6035. PubMed ID: 28151911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graves' Disease: Can It Be Cured?
    Wiersinga WM
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):29-38. PubMed ID: 30912336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genotype-phenotype correlation between null-allele mutations in the ferrochelatase gene and liver complication in patients with erythropoietic protoporphyria.
    Minder EI; Gouya L; Schneider-Yin X; Deybach JC
    Cell Mol Biol (Noisy-le-grand); 2002 Feb; 48(1):91-6. PubMed ID: 11929053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of overt autoimmune hyperthyroidism in a patient therapeutically immunosuppressed after liver transplantation.
    Khovidhunkit W; Greenspan FS; Jaume JC
    Thyroid; 2000 Sep; 10(9):829-32. PubMed ID: 11041462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Graves' Orbitopathy occurring in a patient with thyroid hemiagenesis.
    Meringolo D; Campi I; Costante G
    Endocrine; 2018 Nov; 62(2):490-491. PubMed ID: 29987702
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
    Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of murine erythropoietic protoporphyria-associated skin photosensitivity and liver disease by dermal and hepatic ferrochelatase.
    Pawliuk R; Tighe R; Wise RJ; Mathews-Roth MM; Leboulch P
    J Invest Dermatol; 2005 Jan; 124(1):256-62. PubMed ID: 15654982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
    Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
    Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple nutritional factors and thyroid disease, with particular reference to autoimmune thyroid disease.
    Rayman MP
    Proc Nutr Soc; 2019 Feb; 78(1):34-44. PubMed ID: 30208979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability.
    Barman-Aksözen J; Minder EI; Schubiger C; Biolcati G; Schneider-Yin X
    Blood Cells Mol Dis; 2015 Jan; 54(1):71-7. PubMed ID: 25179834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study.
    Minder AE; Barman-Aksoezen J; Schmid M; Minder EI; Zulewski H; Minder CE; Schneider-Yin X
    Ther Adv Rare Dis; 2021; 2():26330040211065453. PubMed ID: 37181106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
    J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid-stimulating antibody in a patient with euthyroid Graves' disease.
    Kubo T; Toki J; Kado Y; Kurihara M; Moriwake T; Kanzaki S; Seino Y
    Endocr J; 2000 Apr; 47(2):197-201. PubMed ID: 10943745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The incidence of the pituitary autoantibodies in Graves' disease].
    Gut P; Kosowicz J; Ziemnicka K; Baczyk M; Sawicka J; Czarnywojtek A; Sowiński J
    Endokrynol Pol; 2007; 58(3):195-200. PubMed ID: 17940984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum thyrotropin in Graves' disease: a more reliable index of circulating thyroid-stimulating immunoglobulin level than thyroid function?
    Kabadi UM; Premachandra BN
    Endocr Pract; 2007 Oct; 13(6):615-9. PubMed ID: 17954417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.